Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Missling himself said around 300 patients so that point is moot debating.

Revamping the FDA guidelines helps speed up the process of getting access of said drug to patient, as long as it is safe. So again, 2-3 years is a bit far fetched. Especially with 25 patients already in the 2-3 year realm and still providing useful data. So the p2a/b continuing data along with the p2/3 at even 1 year would get the longs here across the finish line.

With Axon, NTRP, BIIB and every other BP failing to provide a better than soc treatment for Alz, it's taking the little pharmas to lead the charge and discover new possibilities only to then get bought out by BP. Now, do you REALLY think BIIB didn't try and buy Anavex on the cheap?